Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Lennart Ahnfelt"'
Publikováno v:
Acta Orthopaedica. 78:730-738
In uncemented total hip arthroplasty with hydroxyapatite coating, early weight bearing is frequently practiced but there is still not much evidence to support this recommendation.In a prospective randomized study we evaluated the effect of partial an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab2a73958f8a48824182a7f8a98eac85
https://doi.org/10.1080/17453670710014491
https://doi.org/10.1080/17453670710014491
Autor:
Nadia Rosencher, Piovella F, Paul A. Reilly, Rohan Hettiarachchi, Harry R. Büller, Bravo Ml, Ola E. Dahl, Peter Kälebo, Joachim Stangier, Lennart Ahnfelt, Bengt I. Eriksson
Publikováno v:
Journal of thrombosis and haemostasis, 3(1), 103-111. Wiley-Blackwell
Summary. Background: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery. Methods: In a multicenter, parallel-group, double-blind study, 1973
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4066dc1637e2ad4bc34732b721bbae39
https://doi.org/10.1111/j.1538-7836.2004.01100.x
https://doi.org/10.1111/j.1538-7836.2004.01100.x
Autor:
K. Hermansson, V. Kohlbrenner, Bengt I. Eriksson, Lennart Ahnfelt, Gerhard Nehmiz, Ola E. Dahl, Peter Kälebo, Joachim Stangier
Publikováno v:
Journal of Thrombosis and Haemostasis. 2:1573-1580
Summary. Background: Dabigatran etexilate (BIBR 1048) is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following total hip replacement. Following oral administration, dabigatran etexilate i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::689064003522721842adf52a6fa748d2
https://doi.org/10.1111/j.1538-7836.2004.00890.x
https://doi.org/10.1111/j.1538-7836.2004.00890.x
Autor:
Ann-Christin Arfwidsson, Lennart Ahnfelt, Christine Sareyko Elvander, Lars Frison, Åke Sjöstedt, Ulf Eriksson, Sven Björkström, Mats Ögren, Peter Kälebo, Agnetha Folestad, Bengt I. Eriksson
Publikováno v:
Thrombosis Research. 105:371-378
The first clinical studies evaluating the safety and efficacy of melagatran, a novel, direct thrombin inhibitor, given subcutaneously as prophylaxis for venous thromboembolism (VTE) following total hip (THR) or total knee replacement (TKR) are report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffe2836c0d3cc1e68dbb895dee106dc5
https://doi.org/10.1016/s0049-3848(02)00038-5
https://doi.org/10.1016/s0049-3848(02)00038-5
Publikováno v:
Acta Orthopaedica Scandinavica. 63:403-406
We studied four different methods of registration of dislocations after total hip arthroplasty (THA) carried out at Malmö General Hospital during 1979-1988. Established registers failed to incorporate more than half of the dislocations and approxima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::286f443d9ccfd0518cc6c43282dcf58b
https://doi.org/10.3109/17453679209154754
https://doi.org/10.3109/17453679209154754
Publikováno v:
Acta Orthopaedica Scandinavica. 61:2-26
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfa2094b9025727dcd86fcfda9bb7e17
https://doi.org/10.3109/17453679009153919
https://doi.org/10.3109/17453679009153919
Autor:
Robbyna Svard, Hildegard Stähle, Lennart Ahnfelt, Joachim Stangier, Karin Rathgen, Ola E. Dahl, Gerhard Nehmiz, Bengt I. Eriksson
Publikováno v:
Journal of clinical pharmacology. 45(5)
Dabigatran etexilate is an oral low-molecular-weight direct thrombin inhibitor. Following oral administration, dabigatran etexilate is rapidly converted to its active form, dabigatran. The authors investigated the absorption, distribution, and elimin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::050b480983d7fbf24f34c20d94277a2a
https://pubmed.ncbi.nlm.nih.gov/15831779
https://pubmed.ncbi.nlm.nih.gov/15831779
Autor:
Bengt I, Eriksson, Mats, Ogren, Ulf G, Eriksson, Peter, Kälebo, Lennart, Ahnfelt, Sven, Björkström, Ake, Sjöstedt, Agnetha, Folestad, Ann-Christin, Arfwidsson, Christine Sareyko, Elvander, Lars, Frison
Publikováno v:
Thrombosis research. 105(5)
The first clinical studies evaluating the safety and efficacy of melagatran, a novel, direct thrombin inhibitor, given subcutaneously as prophylaxis for venous thromboembolism (VTE) following total hip (THR) or total knee replacement (TKR) are report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a006069982f8c6e736dd455663b14827
https://pubmed.ncbi.nlm.nih.gov/12062537
https://pubmed.ncbi.nlm.nih.gov/12062537
Publikováno v:
Acta orthopaedica Scandinavica. 64(5)
A prospective, national multi-center study of all reoperations after total hip replacement (THR) was started by the Swedish Orthopedic Association in 1979. The material comprises all THR performed in Sweden, presently more than 10,000 yearly or 130 T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70e7519052c262beaaccfa694b57a3a8
https://pubmed.ncbi.nlm.nih.gov/8237312
https://pubmed.ncbi.nlm.nih.gov/8237312
Publikováno v:
Clinical Orthopaedics and Related Research. 333:226
The dislocation rate of 3197 Charnley prostheses with 22 mm head in which the surgery was done between 1979 and 1991 in 2 orthopaedic centers was compared with that of 2875 Lubinus prostheses with 32 mm head in which the surgery was done between 1980
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44fb9bbca1fc063cadb1301feed41f8b
https://doi.org/10.1097/00003086-199612000-00024
https://doi.org/10.1097/00003086-199612000-00024